The CASP2 mRNA level was significantly upregulated in AML BM EPCs (Fig. 6H, 6.43 ± 0.89-fold vs. 2.28 ± 0.56-fold, P = 0.03) compared to higher-risk MDS BM EPCs. Here, CASP2 is linked to myelodysplastic syndrome.